Evogene (EVGN) Receivables - Other (2012 - 2025)
Evogene (EVGN) posted Receivables - Other of $1.6 million for Q4 2025, down 3.04% sequentially from $1.6 million in Q3 2025, and down 24.18% YoY from $2.1 million in Q4 2024.
Evogene (EVGN) Receivables - Other (2012 - 2025) Analysis & Trends
Evogene has reported Receivables - Other for 14 years, with the latest figure at $1.6 million in Q4 2025.
- Quarterly Receivables - Other fell 24.18% year-over-year to $1.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.6 million (down 24.18% YoY) and the FY2025 annual result came in at $1.6 million, down 24.18% from the prior year.
- Receivables - Other eased to $1.6 million in Q4 2025 per EVGN's latest filing, from $1.6 million in the prior quarter.
- Over five years, Receivables - Other peaked at $3.7 million in Q2 2024 and troughed at $651000.0 in Q1 2025.
- A 5-year average of $2.1 million and a median of $2.1 million in 2022 frame the typical range for Receivables - Other.
- The sharpest annual moves came in 2024 and 2025: Receivables - Other surged 160.47% in 2024, then tumbled 81.6% in 2025.
- Over 5 years, Receivables - Other stood at $2.7 million in 2021, then tumbled by 44.1% to $1.5 million in 2022, then soared by 100.61% to $3.0 million in 2023, then slumped by 30.58% to $2.1 million in 2024, then decreased by 24.18% to $1.6 million in 2025.
- According to Business Quant data, Receivables - Other over the past three periods registered $1.6 million, $1.6 million, and $680000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Evogene | 4.38 Mn | 4.38 Mn | 204,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.57 Mn |
| Dec 31, 2025 | 1.57 Mn |
| Sep 30, 2025 | 1.61 Mn |
| Sep 30, 2025 | 1.61 Mn |
| Jun 30, 2025 | 680,000.00 |
| Jun 30, 2025 | 680,000.00 |
| Mar 31, 2025 | 651,000.00 |
| Mar 31, 2025 | 651,000.00 |
| Dec 31, 2024 | 2.06 Mn |
| Dec 31, 2024 | 2.06 Mn |
| Sep 30, 2024 | 2.36 Mn |
| Sep 30, 2024 | 2.36 Mn |
| Jun 30, 2024 | 3.70 Mn |
| Jun 30, 2024 | 3.70 Mn |
| Mar 31, 2024 | 3.15 Mn |
| Mar 31, 2024 | 3.15 Mn |
| Dec 31, 2023 | 2.97 Mn |
| Dec 31, 2023 | 2.97 Mn |
| Sep 30, 2023 | 1.87 Mn |
| Sep 30, 2023 | 1.87 Mn |